GC
AXNX

Guggenheim Capital’s Axonics, Inc. Common Stock AXNX Stock Holding History

Guggenheim Capital’s Portfolio AXNX Stock Details AXNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28,398
Closed -$1.98M – 1950
2024
Q3 		$1.98M Sell
28,398
-12,087
-30% -$829K 0.01% 823
2024
Q2 		$2.72M Sell
40,485
-313
-0.8% -$21.1K 0.02% 717
2024
Q1 		$2.81M Sell
40,798
-21,950
-35% -$1.48M 0.02% 763
2023
Q4 		$3.9M Sell
62,748
-288
-0.5% -$16.1K 0.03% 607
2023
Q3 		$3.54M Buy
63,036
+10,537
+20% +$593K 0.03% 608
2023
Q2 		$2.65M Buy
52,499
+2,518
+5% +$134K 0.02% 740
2023
Q1 		$2.73M Buy
49,981
+6,913
+16% +$404K 0.02% 748
2022
Q4 		$2.69M Sell
43,068
-1,662
-4% -$110K 0.02% 739
2022
Q3 		$3.15M Buy
44,730
+14,499
+48% +$1M 0.03% 671
2022
Q2 		$1.71M Buy
30,231
+4,548
+18% +$249K 0.01% 959
2022
Q1 		$1.61M Buy
+25,683
New +$1.38M 0.01% 1127

Other funds holding AXNX

TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Guggenheim Capital's AXNX Position: Q4 2024 in Review

Guggenheim Capital sold out of Axonics, Inc. Common Stock (AXNX) in Q4 2024, closing a stake of 28,398 shares — an estimated $1.98M sold.

Guggenheim Capital first reported a position in AXNX in Q1 2022 and held it in 11 quarters. The position peaked at $3.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold AXNX as of Q4 2024.

  • Guggenheim Capital reported no remaining Axonics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Guggenheim Capital sold 28,398 Axonics, Inc. Common Stock shares in Q4 2024, an estimated $1.98M.
  • Guggenheim Capital first reported a position in Axonics, Inc. Common Stock in Q1 2022 and held it in 11 quarters.
  • Guggenheim Capital's Axonics, Inc. Common Stock position peaked at $3.9M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q4 2024.

Based on Guggenheim Capital's 13F filing for Q4 2024, filed 13 Feb 2025.